A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-05-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the
blood stream and how long it takes the body to get rid of it, when given via pre-filled
syringe compared to mirikizumab (reference) solution given via pre-filled syringe. The
information about any adverse effects experienced will be collected and the tolerability of
mirikizumab will also be evaluated.
Screening is required within 35 days prior to enrolment. For each participant, the total
duration of the clinical trial will be about 17 weeks including screening.